products. Sec. 302. REMS approval process for subsequent filers. Sec. 303. Rule of construction. Subtitle B—Pay-for-Delay Sec. 311. Unlawful agreements. Sec. 312. Notice and certification of agreements. Sec. 313. Forfeiture of 180-day exclusivity period. Sec. 314. Commission litigation authority. Sec. 315. Statute of limitations. Subtitle C—BLOCKING Act Sec. 321. Change conditions of first generic exclusivity to spur access and competition. Subtitle D—Purple Book Sec. 331. Public listing. Sec. 332. Review and report on types of information to be listed. Subtitle E—Orange Book Sec. 341. Orange Book. Sec. 342. GAO report to Congress. Subtitle F—Advancing Education on Biosimilars Sec. 351. Education on biological products. Subtitle G—Streamlining Transition of Biological Products Sec. 361. Streamlining the transition of biological products. Subtitle H—Over-the-Counter Monograph Safety, Innovation, and Reform Sec. 370. Short title